ASK1 inhibitors, GS-444217 and GS-4997 have been shown to have a renoprotective effect in several in vivo animal models of kidney disease and are currently in clinical trials for treatment of DKD [197]. This evidence concerns the gene MAP3K5 and diabetic kidney disease.